ADL5945 0.25 mg

DRUG2 trials

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

ConstipationOpioid Induced Constipation

Phase 2

Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain

CompletedNCT01207427

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Opioid Induced Constipation

Start: 2010-10-14End: 2011-06-28Updated: 2018-09-25

Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain

CompletedNCT01275755

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Constipation

Start: 2011-01-19End: 2011-07-15Updated: 2018-11-15